Biosimilar Safety and Efficacy Comparable to Biologic Treatment in IBD Patients

Biologic compounds have long been considered the gold standard immunosuppressive therapy for moderate-to-severe IBD, but growing evidence suggests that biosimilars offer similar benefits at a much lower cost. Now, a new Cleveland Clinic study comparing the biologic compound infliximab with the biosimilar infliximab-abda shows that the two therapies are comparable in both safety and efficacy

Impact of Biologics Use on Bone Loss in Patients with IBD

IBD patients treated with biologics are significantly less likely to have osteoporosis and bone fractures compared with those who did not, according to the largest individual study to date investigating the prevalence of osteoporosis and bone fractures in IBD patients with and without biologics therapy.

Cutaneous Adverse Effects of Surface-Targeted Monoclonal Antibodies

Biologic therapies, such as surface-targeted monoclonal antibodies, have revolutionized medicine and offer targeted therapy for an increasing number of diseases; however, along with these advances and their ensuing expanded use have come many unique adverse effects. In this article, dermatologists review how to manage these adverse effects and when to consult a dermatologist.

Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors

Biologic therapies, such as epidermal growth factor receptor inhibitors, have revolutionized medicine and offer targeted therapy for an increasing number of diseases; however, along with these advances and their ensuing expanded use have come many unique adverse effects. In this article, dermatologists review how to manage cutaneous adverse effects of EFGR inhibitors and when to consult a dermatologist.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Cutaneous Adverse Effects of Biologic Medications

Biologic therapies have revolutionized medicine and offer targeted therapy for an increasing number of diseases; however, along with these advances and their ensuing expanded use have come many unique adverse effects. In this series, dermatologists discuss management strategies for cutaneous adverse effects from biologics.

Advertising Policy

Breaking Down Biologic Use in Severe Asthma

The development and availability of biologic agents to target specific pathophysiological elements of severe asthma has altered the landscape of care. Our asthma experts break down biologic use for patients with severe asthma.